









Markets
/
Stocks
/
nasdaq-tlsi
/

TriSalus Life Sciences Inc

TLSI

4.900USD

-0.020-0.41%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

186.12MMarket Cap

LossP/E TTM



TriSalus Life Sciences Inc

4.900

-0.020-0.41%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

134 / 506

Overall Ranking

242 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

11.500

Target Price

+133.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 137.39% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 29.43M.

Fairly Valued

The company’s latest PE is -4.24, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 22.46M shares, increasing 10.38% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 814.39K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.37, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.21M, representing a year-over-year increase of 52.27%, while its net profit experienced a year-over-year increase of 75.38%.

Score

Industry at a Glance

Previous score

8.37

Change



Financials

6.74

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.94

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.62

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.53

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -4.26, which is -67.39% below the recent high of -1.39 and -10.36% above the recent low of -4.70.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 134/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for TriSalus Life Sciences Inc is 11.00, with a high of 16.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

11.500

Target Price

+133.74%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

TriSalus Life Sciences Inc

TLSI

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.03, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 5.37 and the support level at 4.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.03

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Neutral

RSI(14)

53.378

Neutral

STOCH(KDJ)(9,3,3)

63.264

Buy

ATR(14)

0.276

High Vlolatility

CCI(14)

22.080

Neutral

Williams %R

42.690

Buy

TRIX(12,20)

0.148

Sell

StochRSI(14)

92.843

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

4.790

Buy

MA10

4.770

Buy

MA20

4.924

Sell

MA50

4.621

Buy

MA100

4.935

Sell

MA200

5.036

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 64.15%, representing a quarter-over-quarter decrease of 1.62%. The largest institutional shareholder is The Vanguard, holding a total of 814.39K shares, representing 1.63% of shares outstanding, with 7.25% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Frankenius Equity AB

6.23M

Pallotta (James Joseph)

2.15M

+19.50%

Utmost Group PLC

2.00M

Wahlstrom (Mats)

1.30M

+1.98%

HW Investment Partners LLC

1.37M

Sands Point LLC

1.13M

Gilder Gagnon Howe & Co. LLC

827.36K

+5637.57%

Hicks (Kerry R)

919.17K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.60, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.